[Delay in the introduction of treatment modalities for neuroendocrine tumors in Japan].
The incidence of pancreatic-intestinal neuroendocrine tumors is rapidly increasing worldwide, and intensive research has been carried out for the standardization of its treatment. In Japan, a few diagnostic and treatment modalities including somatostatin receptor scintigraphy(SRS)have not been approved by the government. Therefore, we intend to improve this situation as soon as possible.